Newsroom
Approximately 350 to 400 new cases of colorectal cancer are diagnosed in Cyprus each year, making it the island's third most common cancer. This information was shared during a press conference held in Nicosia, marking European Colorectal Cancer Awareness Month.
The Cyprus Gastroenterology Society, the Pancyprian Medical Association, and pharmaceutical company Medochemie have partnered to promote awareness and early detection of the disease. Experts at the press conference stressed the critical role of preventive screenings, suggesting they could potentially address a significant portion of diagnosed cases.
Dr. Andreas Evgeniou, President of the Cyprus Gastroenterology Society, stated that Cyprus maintains a relatively high five-year survival rate for colorectal cancer, reaching 72.1%. This figure surpasses the European Union average of 60%. He also emphasized that countries with established prevention programs have seen substantial reductions in mortality rates, ranging from 30% to 50%. Dr. Evgeniou expressed hope for the implementation of a national screening program in Cyprus.
Dr. Loizos Loizou, a board member of the Cyprus Gastroenterology Society, reported an observed increase in the aggressiveness of colorectal cancer, with diagnoses occurring at more advanced stages and affecting younger individuals. He attributed this trend to lifestyle and dietary changes and called for government action through preventative screening programs.
Dr. Petros Agathangelou, President of the Pancyprian Medical Association, commended the collaborative awareness initiative. Nikolas Christidis, Sales Director of Medochemie, reiterated the company's commitment to public health and support for initiatives aimed at improving quality of life.
Colorectal cancer is a significant global health concern, recognized as the third most common cancer in humans and the most prevalent gastrointestinal cancer. In Europe, it ranks as the second leading cause of cancer-related deaths, following lung cancer. While it primarily affects individuals over 50, there has been a noted increase in cases among younger populations.
